Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma
Sponsor: Shanghai Zhongshan Hospital
Summary
This study aims to investigate the efficacy and safety of SHR-1701 in combination with famitinib in the perioperative treatment of mucosal melanoma
Official title: A Multicenter, Phase II Clinical Trial of Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma (The ASPRIE-MM Study)
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2026-04-01
Completion Date
2028-12-30
Last Updated
2026-04-08
Healthy Volunteers
No
Conditions
Interventions
SHR-1701
Specifically targets mucosal melanoma, which accounts for 22.6% of melanoma cases in China
Famitinib
Specifically targets mucosal melanoma, which accounts for 22.6% of melanoma cases in China